MX2017015302A - Agentes nucleosidos para la reduccion de la actividad perjudicial de los genes que contienen repeticiones de nucleotidos extendidas. - Google Patents

Agentes nucleosidos para la reduccion de la actividad perjudicial de los genes que contienen repeticiones de nucleotidos extendidas.

Info

Publication number
MX2017015302A
MX2017015302A MX2017015302A MX2017015302A MX2017015302A MX 2017015302 A MX2017015302 A MX 2017015302A MX 2017015302 A MX2017015302 A MX 2017015302A MX 2017015302 A MX2017015302 A MX 2017015302A MX 2017015302 A MX2017015302 A MX 2017015302A
Authority
MX
Mexico
Prior art keywords
activity
nucleotide repeat
reduction
reducing
target gene
Prior art date
Application number
MX2017015302A
Other languages
English (en)
Inventor
N Cohen Stanley
Deng Ning
Feng Yanan
Hao Cheng Tzu-
Yun WU Yun-
Chieh HSIEH Wen-
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of MX2017015302A publication Critical patent/MX2017015302A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

Los aspectos de la invención incluyen métodos para la reducción de la actividad perjudicial de un gen objetivo que contiene una repetición de nucleótidos (NR, por sus siglas en inglés) extendida mutante en una célula mediante el contacto de la célula con una cantidad eficaz de un agente nucleósido, así como también composiciones utilizadas en dichos métodos; la actividad perjudicial (por ejemplo, toxicidad y/o disfuncionalidad de los productos codificados por este) de un gen objetivo que contiene NR extendida mutante puede verse reducida en una variedad de diferentes formas, por ejemplo, mediante la reducción (y en algunos casos reducción diferencial, que incluye selectiva) la producción o actividad de los productos de expresión tóxica (por ejemplo, ARN o proteína) codificados por el gen objetivo; se proporcionan también kits y composiciones para poner en práctica los métodos objeto.
MX2017015302A 2015-05-29 2016-05-18 Agentes nucleosidos para la reduccion de la actividad perjudicial de los genes que contienen repeticiones de nucleotidos extendidas. MX2017015302A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562168558P 2015-05-29 2015-05-29
PCT/US2016/033116 WO2016196012A1 (en) 2015-05-29 2016-05-18 Nucleoside agents for the reduction of the deleterious activity of extended nucleotide repeat containing genes

Publications (1)

Publication Number Publication Date
MX2017015302A true MX2017015302A (es) 2018-03-28

Family

ID=57442140

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017015302A MX2017015302A (es) 2015-05-29 2016-05-18 Agentes nucleosidos para la reduccion de la actividad perjudicial de los genes que contienen repeticiones de nucleotidos extendidas.

Country Status (16)

Country Link
US (1) US10675293B2 (es)
EP (1) EP3303588A4 (es)
JP (1) JP2018520111A (es)
KR (1) KR20180030461A (es)
CN (1) CN107614686A (es)
AU (1) AU2016270297B2 (es)
BR (1) BR112017022578A2 (es)
CA (1) CA2978521A1 (es)
CL (1) CL2017002608A1 (es)
CO (1) CO2017011617A2 (es)
CR (1) CR20170544A (es)
EA (1) EA201792261A1 (es)
IL (1) IL254304A0 (es)
MX (1) MX2017015302A (es)
SG (1) SG11201707513QA (es)
WO (1) WO2016196012A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6990369B2 (ja) * 2017-05-19 2022-02-03 国立大学法人 熊本大学 遺伝性腎疾患アルポート症候群治療薬に係る評価系
AU2018288771B2 (en) * 2017-06-19 2022-04-14 Thomas W. Sun Compounds for the reduction of the deleterious activity of extended nucleotide repeat containing genes
US10882821B1 (en) 2017-09-26 2021-01-05 The Board Of Trustees Of The Leland Stanford Junior University Enantiomeric compound for the reduction of the deleterious activity of extended nucleotide repeat containing genes
US11891601B2 (en) * 2018-01-22 2024-02-06 National Yang Ming Chiao Tung University Method to enhance the transcription regulation of SUPT4H on genes containing repetitive nucleotide sequences

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968914A (en) * 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
US5470838A (en) 1987-10-28 1995-11-28 Pro-Neuron, Inc. Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
WO1995018616A2 (en) 1994-01-03 1995-07-13 Acea Pharm Inc 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/nmda receptor
US7807654B2 (en) 1998-08-31 2010-10-05 Wellstat Therapeutics Corporation Compositions and methods for treatment of mitochondrial diseases
US6472378B2 (en) 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US7915233B1 (en) 1998-08-31 2011-03-29 Wellstat Therapeutics Corporation Compositions and methods for treatment of mitochondrial diseases
DK1171137T3 (da) 1999-02-23 2008-03-31 Univ California Anvendelse af triacetyluridin til behandling af mitochondriale lidelser
CA2388192A1 (en) 1999-10-26 2001-05-03 Deltagen, Inc. Transgenic mice containing trp gene disruptions
US20050277133A1 (en) 2001-05-18 2005-12-15 Sirna Therapeutics, Inc. RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
US20050096284A1 (en) 2002-02-20 2005-05-05 Sirna Therapeutics, Inc. RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
US20080176812A1 (en) 2002-08-05 2008-07-24 Davidson Beverly L Allele-specific silencing of disease genes
CA2881743A1 (en) 2002-09-25 2004-04-08 University Of Massachusetts In vivo gene silencing by chemically modified and stable sirna
AU2003261405A1 (en) 2002-11-01 2004-06-07 University Of Massachusetts Regulation of transcription elongation factors
WO2004064734A2 (en) * 2003-01-17 2004-08-05 Threshold Pharmaceuticals, Inc. Combination therapies for the treatment of cancer
US20050037992A1 (en) 2003-07-22 2005-02-17 John Lyons Composition and method for treating neurological disorders
DK2821085T3 (da) 2003-09-12 2020-08-03 Univ Massachusetts Rna-interferens til behandling af "gain-of-function"-forstyrrelser
US8680063B2 (en) 2003-09-12 2014-03-25 University Of Massachusetts RNA interference for the treatment of gain-of-function disorders
GB2442881B (en) 2005-03-25 2010-08-04 Uab Research Foundation Methods for altering gene expression and methods of treatment utilizing same
EP2581440B1 (en) 2005-06-08 2016-03-16 The University of North Carolina At Chapel Hill Methods of facilitating neural cell survival using non-peptide and peptide BDNF neurotrophin mimetics
US20070105803A1 (en) 2005-08-18 2007-05-10 Muthiah Manoharan Methods and compositions for treating neurological disease
US8129357B2 (en) * 2006-04-07 2012-03-06 Academia Sinica Method of making and using an adenosine analogue
US7375190B2 (en) 2006-09-19 2008-05-20 National Yang-Ming University Recombinant protein and method of screening for agents that modulate polypeptide aggregation
US9234016B2 (en) 2009-07-28 2016-01-12 Sangamo Biosciences, Inc. Engineered zinc finger proteins for treating trinucleotide repeat disorders
KR101774526B1 (ko) 2009-09-11 2017-09-04 아이오니스 파마수티컬즈, 인코포레이티드 헌팅틴 발현의 조절
EP2498774B1 (en) * 2009-11-13 2017-10-11 Academia Sinica Dual-action compounds targeting adenosine a2a receptor and adenosine transporter for prevention and treatment of neurodegenerative diseases
WO2011097641A1 (en) 2010-02-08 2011-08-11 Isis Pharmaceuticals, Inc. Methods and compositions useful in treatment of diseases or conditions related to repeat expansion
US8569254B2 (en) 2010-12-10 2013-10-29 National Yang Ming University Methods for modulating the expression and aggregation of CAG-expanded gene product in cells and methods for identifying agents useful for doing the same
US8618077B2 (en) * 2011-04-28 2013-12-31 Emory University Compositions and methods for treating fragile X premutation RVGG repeats-mediated toxicity
CN107353316B (zh) 2011-09-30 2020-08-18 塔夫斯大学 用于治疗神经变性疾病的尿苷二磷酸衍生物、组合物和方法
EP3060566B1 (en) * 2013-10-23 2018-09-05 Academia Sinica Compounds for use in prevention and treatment of neurodegenerative diseases and pain

Also Published As

Publication number Publication date
IL254304A0 (en) 2017-11-30
EP3303588A4 (en) 2019-01-23
AU2016270297A1 (en) 2017-09-21
KR20180030461A (ko) 2018-03-23
CN107614686A (zh) 2018-01-19
CO2017011617A2 (es) 2018-02-09
CL2017002608A1 (es) 2018-06-29
CR20170544A (es) 2018-03-20
AU2016270297B2 (en) 2019-12-12
US10675293B2 (en) 2020-06-09
EA201792261A1 (ru) 2018-04-30
CA2978521A1 (en) 2016-12-08
WO2016196012A1 (en) 2016-12-08
SG11201707513QA (en) 2017-10-30
JP2018520111A (ja) 2018-07-26
US20180064744A1 (en) 2018-03-08
BR112017022578A2 (pt) 2018-07-17
EP3303588A1 (en) 2018-04-11

Similar Documents

Publication Publication Date Title
MX2020013357A (es) Polimerasas, composiciones y metodos de uso.
MX2020013347A (es) Polimerasas, composiciones y metodos de uso.
CY1125364T1 (el) Συνθεσεις και μεθοδοι για την αναστολη της εκφρασης του γονιδιου ηαο1 (οξειδαση υδροξυοξεος 1 (γλυκολικη οξειδαση)
MX2021004187A (es) Métodos y composiciones para editar ácidos ribonucleicos.
MX2022003116A (es) Factor ix modificado, y composiciones, metodos y usos para la transferencia de genes a celulas, organos y tejidos.
WO2016057951A3 (en) Crispr oligonucleotides and gene editing
WO2017044857A3 (en) Methods and compositions for the treatment of glaucoma
WO2017019660A8 (en) Xanthine dehydrogenase (xdh) irna compositions and methods of use thereof
WO2016106400A3 (en) Rna interference agents for gst-pi gene modulation
MX2016009243A (es) Métodos de mutagénesis.
MX2015008697A (es) Tratamiento contra la degeneración macular relacionada con la edad.
MX2021010668A (es) Proteinas de fusion de citoquinas.
MX2020003339A (es) Arn guía de cpf1 modificado.
WO2016065349A8 (en) Short non-coding protein regulatory rnas (sprrnas) and methods of use
MX2017015302A (es) Agentes nucleosidos para la reduccion de la actividad perjudicial de los genes que contienen repeticiones de nucleotidos extendidas.
MX2019002699A (es) Terapia genica para pacientes con anemia de fanconi.
MX2020000154A (es) Composiciones y métodos para inhibir la expresión de hmgb1.
MX2019005101A (es) Microarns modificados con 5-halouracilo y su uso en el tratamiento del cancer.
WO2014145870A3 (en) Novel compositions, methods and kits for blood typing
MX2019006552A (es) Terapia génica para mucopolisacaridosis de tipo i.
PH12019500239A1 (en) High throughput cell-based screening for aptamers
MX2015012063A (es) Oligonucleotidos antisentido para el tratamiento de celulas madre del cancer.
WO2017059122A8 (en) Methods of treating and preventing amyotrophic lateral sclerosis
MX2019005149A (es) Arn bicatenario con modificaciones quimicas postranscripcionales.
WO2015020993A3 (en) RNAi COMPOSITIONS AND METHODS FOR TREATMENT OF FRIEDREICH'S ATAXIA